Big data analysis of global advances in pharmaceutics and drug delivery 1980–2014

Zhang, Weixiang; Zhao, Qianqian; Deng, Junling; Y, Hu; Wang, Ying; Ouyang, Defang

doi:10.1016/j.drudis.2017.05.012

Cited by 17 publications

(9 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These advanced drug delivery systems (DDSs) are widely studied in both academia and the pharmaceutical industry [39]. There has been a dramatic increase in the publication number and clinical trials on novel DDSs during the past three decades [40]. However, an obvious gap can be viewed between product output and research input.…”

Section: The Analysis Of Advanced Ddssmentioning

confidence: 99%

A Comprehensive Map of FDA-Approved Pharmaceutical Products

Zhong¹,

Chan²,

Y³

et al. 2018

Pharmaceutics

Self Cite

226

143

View full text Add to dashboard Cite

With the increasing research and development (R&D) difficulty of new molecular entities (NMEs), novel drug delivery systems (DDSs) are attracting widespread attention. This review investigated the current distribution of Food and Drug Administration (FDA)-approved pharmaceutical products and evaluated the technical barrier for the entry of generic drugs and highlighted the success and failure of advanced drug delivery systems. According to the ratio of generic to new drugs and the four-quadrant classification scheme for evaluating the commercialization potential of DDSs, the results showed that the traditional dosage forms (e.g., conventional tablets, capsules and injections) with a lower technology barrier were easier to reproduce, while advanced drug delivery systems (e.g., inhalations and nanomedicines) with highly technical barriers had less competition and greater market potential. Our study provides a comprehensive insight into FDA-approved products and deep analysis of the technical barriers for advanced drug delivery systems. In the future, the R&D of new molecular entities may combine advanced delivery technologies to make drug candidates into more therapeutically effective formulations.

show abstract

Section: The Analysis Of Advanced Ddssmentioning

confidence: 99%

A Comprehensive Map of FDA-Approved Pharmaceutical Products

Zhong¹,

Chan²,

Y³

et al. 2018

Pharmaceutics

Self Cite

226

143

View full text Add to dashboard Cite

show abstract

“…The city was extracted from each affiliate to analyze this. This analysis was extracted using the coordination of cities with the open source of online platform gpsvisualizer.com (Zhang, Zhao, Deng, Hu, Wang, & Ouyang, 2017;Garvetto, Badis, Perrineau, Rad-Menendez, Bresnan, & Gachon, 2019). Figure 6 presents the location of the authors who contributed to the low carbon education article.…”

Section: Authors and Co-authorship Relationsmentioning

confidence: 99%

Low Carbon Education: A Review and Bibliometric Analysis

Hudha¹,

Hamidah²,

Permanasari³

et al. 2020

EUROPEAN J ED RES

View full text Add to dashboard Cite

The concept of low carbon education is one solution to provide knowledge to students related to low carbon behavior. The purpose of this paper is providing an extensive bibliometric literature review on 'low carbon education'. Articles found by Publishing or Perish (PoP) software with the Google Scholar database. There were 55 out of 97 articles found from Google Scholar data ba se ranging from 2014 to 2019 analyzed in this study. The chosen references were then managed using a referencing manager software namely Zotero. After managing the database, this study classified and visualized it using VOSviewer software. Overall, this review provides an appropriate reference point for further research on 'low carbon education'.

show abstract

“…Given that the global pharmaceutical industry is estimated to have a turnover in excess of 1 trillion USD, there is obviously a substantial continuing effort to break out of the rut of diminishing returns it finds itself in. Regarding pharmaceutics, the last 30 years has seen the development of increasingly sophisticated mechanisms for enhancing the solubility profile, carrying/protecting drugs in the bloodstream and targeting them to the desired tissue (Zhang W. et al, 2017): the aforementioned nanomedicine (Moghimi et al, 2020). These involve either covalently bonding the drug to a molecule or packaging the drug into a nanoscale (diameter 100nm or less) vehicle that performs this function.…”

Section: Introductionmentioning

confidence: 99%

Mechanistic Understanding From Molecular Dynamics Simulation in Pharmaceutical Research 1: Drug Delivery

Bunker

Róg

2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

In this review, we outline the growing role that molecular dynamics simulation is able to play as a design tool in drug delivery. We cover both the pharmaceutical and computational backgrounds, in a pedagogical fashion, as this review is designed to be equally accessible to pharmaceutical researchers interested in what this new computational tool is capable of and experts in molecular modeling who wish to pursue pharmaceutical applications as a context for their research. The field has become too broad for us to concisely describe all work that has been carried out; many comprehensive reviews on subtopics of this area are cited. We discuss the insight molecular dynamics modeling has provided in dissolution and solubility, however, the majority of the discussion is focused on nanomedicine: the development of nanoscale drug delivery vehicles. Here we focus on three areas where molecular dynamics modeling has had a particularly strong impact: (1) behavior in the bloodstream and protective polymer corona, (2) Drug loading and controlled release, and (3) Nanoparticle interaction with both model and biological membranes. We conclude with some thoughts on the role that molecular dynamics simulation can grow to play in the development of new drug delivery systems.

show abstract

Big data analysis of global advances in pharmaceutics and drug delivery 1980–2014

Cited by 17 publications

References 78 publications

A Comprehensive Map of FDA-Approved Pharmaceutical Products

A Comprehensive Map of FDA-Approved Pharmaceutical Products

Low Carbon Education: A Review and Bibliometric Analysis

Mechanistic Understanding From Molecular Dynamics Simulation in Pharmaceutical Research 1: Drug Delivery

Contact Info

Product

Resources

About